Pharmaceutical Statistics

Table of Contents

Pharmaceutical Statistics - Early View Articles

${pageCtx.sharedData.issuePages}

MAIN PAPERS

Antibiotics to outpatients in N orway—Assessing effect of latitude and municipality population size using quantile regression in a cross‐sectional study

  • Author: Pål Haugen, Gunnar Skov Simonsen, Raul Primicerio, Anne‐Sofie Furberg, Lars Småbrekke
  • Pub Online: Sep 29, 2017
  • DOI: 10.1002/pst.1831 (p )

A dynamic power prior for borrowing historical data in noninferiority trials with binary endpoint

  • Author: G. Frank Liu
  • Pub Online: Nov 10, 2017
  • DOI: 10.1002/pst.1836 (p )

Sample size re‐estimation incorporating prior information on a nuisance parameter

  • Author: Tobias Mütze, Heinz Schmidli, Tim Friede
  • Pub Online: Nov 27, 2017
  • DOI: 10.1002/pst.1837 (p )

Book Reviews

MAIN PAPERS

Response‐adaptive designs for binary responses: How to offer patient benefit while being robust to time trends?

  • Author: Sofía S. Villar, Jack Bowden, James Wason
  • Pub Online: Dec 19, 2017
  • DOI: 10.1002/pst.1845 (p )

Use of a historical control group in a noninferiority trial assessing a new antibacterial treatment: A case study and discussion of practical implementation aspects

  • Author: David Dejardin, Paul Delmar, Charles Warne, Katie Patel, Joost van Rosmalen, Emmanuel Lesaffre
  • Pub Online: Dec 28, 2017
  • DOI: 10.1002/pst.1843 (p )

Comparison of the restricted mean survival time with the hazard ratio in superiority trials with a time‐to‐event end point

  • Author: Bo Huang, Pei‐Fen Kuan
  • Pub Online: Dec 28, 2017
  • DOI: 10.1002/pst.1846 (p )

Development of predictive signatures for treatment selection in precision medicine with survival outcomes

  • Author: Yu‐Chuan Chen, Un Jung Lee, Chen‐An Tsai, James J. Chen
  • Pub Online: Jan 03, 2018
  • DOI: 10.1002/pst.1842 (p )

Integrating dose estimation into a decision‐making framework for model‐based drug development

  • Author: James Dunyak, Patrick Mitchell, Bengt Hamrén, Gabriel Helmlinger, James Matcham, Donald Stanski, Nidal Al‐Huniti
  • Pub Online: Jan 10, 2018
  • DOI: 10.1002/pst.1841 (p )

Approaches to sample size calculation for clinical trials in rare diseases

  • Author: Frank Miller, Sarah Zohar, Nigel Stallard, Jason Madan, Martin Posch, Siew Wan Hee, Michael Pearce, Mårten Vågerö, Simon Day
  • Pub Online: Jan 10, 2018
  • DOI: 10.1002/pst.1848 (p )
Page:   Prev 1 2 3

Related Topics

Related Publications

Related Content

Site Footer

Address:

This website is provided by John Wiley & Sons Limited, The Atrium, Southern Gate, Chichester, West Sussex PO19 8SQ (Company No: 00641132, VAT No: 376766987)

Published features on StatisticsViews.com are checked for statistical accuracy by a panel from the European Network for Business and Industrial Statistics (ENBIS)   to whom Wiley and StatisticsViews.com express their gratitude. This panel are: Ron Kenett, David Steinberg, Shirley Coleman, Irena Ograjenšek, Fabrizio Ruggeri, Rainer Göb, Philippe Castagliola, Xavier Tort-Martorell, Bart De Ketelaere, Antonio Pievatolo, Martina Vandebroek, Lance Mitchell, Gilbert Saporta, Helmut Waldl and Stelios Psarakis.